Vertex Pharmaceuticals
Trade Vertex Pharmaceuticals 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About VRTX
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis.
VRTX Key Statistics
Stock Snapshot
As of today, Vertex Pharmaceuticals(VRTX) shares are valued at $441.20. The company's market cap stands at 111.97B, with a P/E ratio of 31.11.
As of 2026-01-19, Vertex Pharmaceuticals(VRTX) stock has fluctuated between $437.17 and $445.77. The current price stands at $441.20, placing the stock +0.9% above today's low and -1.0% off the high.
The Vertex Pharmaceuticals(VRTX)'s current trading volume is 2.05M, compared to an average daily volume of 1.58M.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $519.68 at its peak.
During the past year, Vertex Pharmaceuticals(VRTX) stock moved between $362.50 at its lowest and $519.68 at its peak.
VRTX News
Vertex Pharmaceuticals recently reported strong 2025 third-quarter results and outlined its 2026 pipeline and business plans, highlighting continued growth in i...
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $438.92, moving -2.36% from the previous trading session. This change lagged the S&P 500's d...
ImmunityBio (NASDAQ:IBRX), a cancer and infectious-disease drug developer, closed Thursday at $3.95, up 30.79% for the session. The stock jumped after prelimina...
Analyst ratings
67%
of 36 ratingsMore VRTX News
In trading on Thursday, shares of Vertex Pharmaceuticals, Inc. (Symbol: VRTX) crossed below their 200 day moving average of $437.70, changing hands as low as $4...
Plenty of growth lies ahead for these top healthcare companies. What makes a winning healthcare stock? One that is a leader in its industry and has proven its...
If you are wondering whether Vertex Pharmaceuticals at around US$454.67 is still a reasonable entry or more of a hold, you are asking the right question for a v...
Advertisement Conference updates and pipeline focus Vertex Pharmaceuticals (VRTX) has drawn fresh attention after outlining business and program updates ahead...
As previously reported, Bernstein analyst William Pickering earlier upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform with a $572 price t...
A look at the weighted underlying holdings of the Fidelity MSCI Health Care Index ETF (Symbol: FHLC) shows an impressive 17.5% of holdings on a weighted basis h...
Bernstein analyst William Pickering upgraded Vertex Pharmaceuticals (VRTX) to Outperform from Market Perform. Published first on TheFly – the ultimate source f...